KALA

KALA BIO, Inc.
CAPPED RATING

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

KALA BIO, Inc. (KALA) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B+
Factor Score 3.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.0
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -81.5%
Price Return 12M -99.5%
Catalyst Signal 0.00
Market Cap $3.3M
TTM Revenue N/A
Price / Sales N/A
ROE -345.3%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B+ (3.7) C+ (2.5) C- (2.1) F (0.3) C+ (2.6) C (2.3)
2026-11-05 A- (3.9) C+ (2.5) C (2.2) F (0.4) C+ (2.7) C (2.3)
2026-10-29 B+ (3.7) C+ (2.5) C (2.2) F (0.4) C+ (2.7) C (2.3)
2026-10-22 B+ (3.7) C+ (2.5) C (2.2) F (0.4) C+ (2.6) C (2.3)
2026-10-15 B+ (3.7) C+ (2.5) C (2.2) F (0.4) C+ (2.6) C (2.3)
Page 1 of 5